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Background: The medication process in the Neonatal Intensive Care Unit (NICU), can 
be challenging in terms of costs, time, and the risk of errors. Newborns, especially if born 
preterm, are more vulnerable to medication errors than adults. Recently, robotic medication 
compounding has reportedly improved the safety and efficiency of the therapeutic process. 
In this study, we analyze the advantages of using the I.V. Station® system in our NICU, 
compared to the manual preparation of injectable drugs in terms of accuracy, cost, and time.
Method: An in vitro experimental controlled study was conducted to analyze 10 injectable 
powdered or liquid drugs. Accuracy was calculated within a 5% difference of the bottle 
weight during different stages of preparation (reconstitution, dilution, and final product). 
The overall cost of manual and automated preparations were calculated and compared. 
Descriptive statistics for each step of the process are presented as mean ± standard 
deviation or median (range).
Results: The median error observed during reconstitution, dilution, and final therapy of the 
drugs prepared by the I.V. Station® ranged within ±5% accuracy, with narrower ranges of 
error compared to those prepared manually. With increasing preparations, the I.V. Station® 
consumed less materials, reduced costs, decreased preparation time, and optimized the 
medication process, unlike the manual method. In the 10 drugs analyzed, the time saved 
from using the I.V. Station® ranged from 16 s for acyclovir to 2 h 57 min for teicoplanin, and 
cost savings varied from 8% for ampicillin to 66% for teicoplanin. These advantages are also 
capable of continually improving as the total amount of final product increases.
Conclusions: The I.V. Station® improved the therapeutic process in our NICU. The 
benefits included increased precision in drug preparation, improved safety, lowered cost, 
and saved time. These advantages are particularly important in areas such as the NICU, 
where the I.V. Station® could improve the delivery of the high complexity of care and a 
large amount of intravenous therapy typically required. In addition, these benefits may 
lead to the reduction in medication errors and improve patient and family care; however, 
additional studies will be required to confirm this hypothesis.
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INTRODUCTION
A significant number of intravenous medications are administered 
in the Neonatal Intensive Care Unit (NICU) daily, and harmful 
medication errors are more likely to occur there compared to 
adult settings (Kaushal et al., 2001). Newborns are particularly 
vulnerable to medication errors, based on the peculiarity of the 
developmental pharmacotherapy (Kearns et al., 2003; Chedoe 
et al., 2007). Prescriptions are expressed per kilogram of body 
weight and require accurate calculation and multiple dilutions 
when administered to preterm low-birth-weight infants. Drug 
pharmacokinetics and pharmacodynamics change dynamically 
based on evolving systems and organs maturation (Tayman et al., 
2011; Allegaert et al., 2013; Allegaert et al., 2014; Allegaert and 
Van Den Anker, 2014). The resulting patient-specific variability 
to drug exposure may threaten drug safety, particularly for 
compounds with a narrow therapeutic range (Samra et al., 2011). 
Lastly, most of the drugs prescribed are still off-label for neonates 
(Conroy et al., 1999).
Given the complexity of all these issues, the medication 
process can be challenging in terms of cost, time, and risk of 
errors, particularly for preterm newborns (Conroy et al., 1999; 
Chappell and Newman, 2004; Kugelman et al., 2008). In order 
to optimize the therapeutic process, many technologic solutions 
have been introduced in clinical practice in recent years, such as 
the use of a computerized physician order entry system (CPOE), 
bar-coded identification, and smart-infusion pumps (Myers et al., 
1998; Bates, 2007; Vardi et al., 2007). Recently, robotic medication 
compounding has demonstrated an improvement in the safety 
and efficiency of the therapeutic process in different settings. 
Robotic devices have been shown to be useful in the preparation 
of chemotherapies, adjuvant medications, and cytotoxic drugs for 
adult patients (Seger et al., 2012; Nam et al., 2016; Iwamoto et al., 
2017; Unluturk et al., 2018; Geersing et al., 2019). In all cases, the 
robot was handled by the hospital pharmacists. To date, there are 
no reports of robotic applications in the neonatal setting.
The I.V. Station® is an automated compounding robot that 
prepares ready-to-administer sterile medications through a fully-
automated process (Omnicell, inc. www.omnicell.com). This 
technology has been specifically developed for the automated 
individualized preparation and distribution of injectable drugs 
ready for use, including drugs requiring multiple dilutions 
(either powdered or in solution). Several studies have already 
demonstrated that the use of the I.V. Station® reduces the rate 
of preparation errors and the waste of injectable drugs (Flynn 
et al., 1997). In this study, we compare the advantages obtained 
from the robot-assisted preparation of injectable drugs by the I.V. 
Station®, to the manual preparation in terms of accuracy, costs, 
and time in our NICU.
MATeRIAls AND MeThODs
study Design
This study was conducted in the NICU of Fondazione IRCCS Ca’ 
Granda Ospedale Maggiore Policlinico in Milan in 2016 for 2 
months after the introduction of the I.V. Station® technology. We 
performed an in vitro experimental controlled study to analyze 
the accuracy, cost, and preparation time of medication with 
robot-assistance compared to manual preparation.
The analysis included 10 injectable drugs that were either 
powdered or liquid. For each drug, 10 manual preparations and 
10 automated preparations were compared, for a total of 200 
samples (100 manual and 100 automated). Prescriptions have 
been made considering a hypothetical newborn patient of 1000 g 
of body weight. Dosages were prescribed based on the pediatric 
and neonatal therapeutic dosage handbook (Taketomo et al., 
2018). The updated annual consumption of each drug calculated 
from January to December 2018 in listed in Table 1.
Samples intended for in vitro analyses were not utilized for 
clinical purposes. Since patients were not directly involved in the 
study, our investigation did not require ethical approval.
Accuracy
Accuracy was calculated as <5% difference in the bottle weight 
during different stages of preparation (reconstitution, dilution, 
and final preparation) for both the manual and automated 
processes. This value reflects the accuracy of the concentration of 
the drug at the end of each step.
Automated-Preparation
Using the I.V. Station®, drugs were prepared and multiple 
controls were performed at different steps, specifically:
• Reconstitution check: for the powdered drugs (Acyclovir, 
Ampicillin, Ampicillin + Sulbactam, Amoxicillin + Clavulanic 
TABle 1 | Drugs, composition, therapeutic dose, and number of annual prescriptions.
Drug Composition Therapeutic dose Administrations/year
Acyclovir powder 20 mg/kg 3 times a day for 14-21 days 33
Ampicillin powder 50 mg/kg 3 times a day for 7 days 6585
Ampicillin+Sulbactam powder 50 mg/kg 2 times/day for 7 days 842
Amoxicillin+Clavulanic Acid powder 50 mg/kg 2 times/day for 7 days 3010
Dobutamine liquid 5 mcg/kg/min 243
Fluconazole liquid 3 mg/kg every 72 hours (prophylaxis) 505
Metronidazole liquid 7,5 mg/kg every 12-24 hours for 14 days 1136
Paracetamol liquid 10 mg/kg every 4-8 hours 2623
Teicoplanin powder 8 mg/kg every 24 hours 139
Vancomycin powder 10 mg/kg every 24-72 hours for 7-21 days 6452
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Acid, Teicoplanin, Vancomycin), the I.V. Station® maintained 
accuracy within a range of ±5% by assessing the weight of the 
solvent injected.
• Dilution check: for drugs requiring dilution (Acyclovir, 
Ampicillin, Ampicillin + Sulbactam, Amoxicillin + Clavulanic 
Acid, Dobutamine, Teicoplanin, Vancomycin), the I.V. Station® 
maintained accuracy within a range of ±5% by assessing the 
weight of the drug injected.
• Final check: for all preparations, the I.V. Station® maintained 
accuracy within a range of ±5% by assessing the weight of the 
final product.
Manual Preparation
Drugs were prepared by 6 nurses with at least 5 years of 
experience working in our NICU. No specific training was 
conducted before starting the study since we considered a 
minimum of 5 years NICU expertise sufficient for the purpose 
of the study.
The following formula was applied as we were aware of the 
density of each drug:
 
•Accuracy measured weight ideal weight% ( - ) / (= ideal weight)×100  
Multiple controls were performed at different steps, specifically:
• Reconstitution check: for powdered drugs (Acyclovir, 
Ampicillin, Ampicillin + Sulbactam, Amoxicillin + Clavulanic 
Acid, Teicoplanin, Vancomycin), the nurse maintained 
accuracy within a range of ±5% by assessing the weight of the 
solvent injected.
• Dilution check: for drugs requiring dilution (Acyclovir, 
Ampicillin, Ampicillin + Sulbactam, Amoxicillin + Clavulanic 
Acid, Dobutamine, Teicoplanin, Vancomycin) the nurse 
maintained accuracy within a range of ±5% by assessing the 
weight of the drug injected.
• Final check: for all preparations, the nurse maintained 
accuracy within a range of ±5% by assessing the weight of the 
final product.
Costs
We calculated and compared the overall cost of the manual 
vs. automated drug preparation, considering a detailed list of 
items including bottles, syringes, needles, caps, solvents, gloves, 
sterile gauze, and stoppers. For manual preparations, costs 
were calculated based on a single dose of medication. For the 
IV Station®, since dilution takes place once, a higher number 
of vials are often needed to obtain the desired concentration 
of the stock solution, from which the IV Station® obtains the 
different doses of medication, but also has a larger amount 
of final product available. Hence, the costs included all the 
materials used to obtain the stock solution; however, multiple 
administrations can be obtained.
The costs of electricity, machine maintenance, days of 
detention due to possible damage or machine failure over the 2 
month observation period were not considered.
Preparation Time
For each manual preparation, we considered the time required 
to walk to the laminar flow hood at nurse’s station, prepare a 
single dose of each drug, prime the intravenous line, and return 
to the patient to begin drug administration. For automated 
compounds, we considered the time required to walk to the I.V. 
Station®, withdraw all the drugs already prepared by the robot, 
return to the laminar flow hood to complete the preparation 
and priming of the intravenous line, and return to the patient to 
begin drug administration.
statistical Analysis
Descriptive statistics for each step of the process are presented 
as mean ± standard deviation or median (range) for both the 
I.V. Station® and manual preparations. The cost of each drug 
preparation is fixed, as a result of calculations based on the value 
of the drug itself and the overall material required. Therefore, a 
statistical comparison between the cost of the I.V. Station® and 
manual preparation cannot be conducted due to the absence 
of variability in the estimates. One-way ANOVA was used to 
compare time savings between the drugs for single preparations. 
Time differences between the I.V. Station® and manual 
preparations are reported. Statistical analysis is not informative 
when studying differences between the I.V. Station® and manual 
accuracy because all values lay in the range of ±5%.
Estimates of costs/savings and preparation times are presented 
using a heatmap plot. Boxplots are used to show the distribution of 
time for each drug analyzed. Statistical analyses were performed 
using R version 3.5.3 (R Foundation for Statistical Computing, 
Vienna, Austria).
ResUlTs
Accuracy
The data concerning the accuracy of manual and robotic preparations 
are depicted in Table 2. For the I.V. Station® preparations, the 
median error observed during reconstitution, dilution, and final 
therapy ranged within ±5% accuracy. Narrow ranges of error were 
observed, and they were always included in the ±5% interval.
In the case of manual preparations, the median error lied in 
the range of ±5% accuracy, with the exception of the Ampicillin 
+ Sulbactam, in which a median error 6.3% was observed during 
the dilution check. Moreover, higher variability and wider ranges 
of error were observed, which sometimes exceeded the ±5% 
limits. Indeed, in 5% of all manual preparations, the accuracy was 
outside the admitted interval between the range of ±5% (Table 2). 
A graphical representation of the accuracy in reconstitution, 
dilution, and final product for manual and robotic preparations 
is depicted in Figures 1A–C.
Cost and savings
The costs related to manual and automatic drug preparations and 
the number of vials needed to be prepared for a single dose of 
medication are listed in Table 3. A projection of the expected 
costs savings with the I.V. Station® compared to manual drug 
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preparation is displayed in Figure 2. For each drug, the number 
of drug preparations needed to amortize the robotic preparation 
is shown. In our study, when a low number of preparations 
was required, the robotic process was more expensive than 
the manual one (red boxes). As the number of preparations 
increased, the I.V. Station® optimized the materials consumed 
and cost, and eventually equaled the cost of manual preparation 
(white boxes) or became even less expensive (green boxes). As 
shown in the heatmap, if a single preparation was considered, 
the manual method was more cost-effective in four out of 10 
cases. However, with the 10 drug preparations analyzed, the I.V. 
Station® led to substantial savings for all the cases considered. 
The expected savings ranged from 8% for ampicillin to 66% for 
teicoplanin and may continue to rise as the total amount of final 
product increased.
Preparation Time
The time needed to prepare each drug separately is shown in 
Figure 3. In almost all cases, the time required to prepare a single 
manual dose was less than 4 min and ranged from 1 min 17 s for 
paracetamol to 3 min 18 s for Amoxicillin + Clavulanic Acid. The 
only exception was with teicoplanin, in which a single preparation 
took up to 18 min 43 s. In this case, the relevant difference was 
due to the difficulty associated with manual reconstitution and 
dilution of the powdered drug.
The median time required for a single I.V. Station® preparation 
was 2 min 59 s. This was in line with a majority of the manual 
results, although it was higher compared to paracetamol, 
fluconazole, and metronidazole (p-value < 0.001) and lower than 
amoxicillin + clavulanic acid (p-value = 0.007) and teicoplanin 
(p-value < 0.001).
Figure 4 shows a projection of the expected time-savings 
associated with the I.V. Station® compared to manual 
preparation. For each drug, the number of administrations 
required to amortize the I.V. Station® preparation times are 
depicted. In our study, when a low number of doses were 
required, the I.V. Station® was more time-consuming than the 
manual method (red boxes) in some instances. For example, 
if we required a single preparation, the I.V. Station® was 
more expensive than the manual method in half of the cases 
analyzed. As the number of preparations increased, the I.V. 
Station® led to a progressive optimization of the preparation 
process (green boxes). The I.V. Station® led to substantial 
time-savings in all the cases analyzed. The time saved ranged 
from 16 s for acyclovir to 2 h and 57 min for teicoplanin and 
may continue to rise even as the total number of medications 
prepared increase.
DIsCUssION
Medication errors are defined as any preventable event that 
can lead to inappropriate medication use or patient harm. 
Errors can occur at any stage in the medication-use process 
(prescribing, transcribing, dispensing, administering, 
monitoring) (Aronson, 2009). The therapeutic process 
includes several stages; each of which are potentially at risk 
for medication errors (Aronson, 2009). Infants who require 
more intensive levels of care are at a higher risk for medication 
errors and potentially fatal errors are three times more likely 
to occur in the NICU than in adult wards (Kaushal et al., 
2001). Prescribing and drug administration challenges place 
newborns at risk of 10-fold and up to 100-fold potentially 
fatal dosing errors (Chappell and Newman, 2004; Taheri 
et al., 2013).
Preterm babies require a more intensive level of care and 
more complex therapy, which exposes them to a higher risk of 
TABle 2 | The accuracy of manual and robotic preparations.
Drug Type
Reconstitution Dilution Final Therapy
Median error% Range% Median error% Range% Median error% Range%
Acyclovir IV 2.6 2.0; 3.8 -0,5 -1.2; 0.8 3.1 2.1; 4.0
M -0.3 -2.9; 2.5 -1.8 -5.5; -0.4 -1.7 -3.1; -0.5
Amoxicillin + Clavulanic Acid IV 2.5 -0.4; 2.8 0.6 0.1; 1.9 0.3 -0.5; 1.4
M -0.2 -3.5; 1.5 4.0 1.0; 5.3 -1.1 -2.3; 0.1
Ampicillin IV 2.1 1.4; 2.6 -1.4 -3.6; 1.3 3.1 2.1; 4.0
M -0.2 -7.7; 6.9 3.9 0.2; 4.3 2.2 -1.4; 5.3
Ampicillin + Sulbactam IV 2.8 2.0; 3.2 -0.5 -2.8; 1.0 -0.4 -1.1; 0.9
M 0.0 -3.6; 3.6 6.3 5.0; 7.1 1.4 -0.4; 3.5
Teicoplanin IV 1.2 -2.4; 1.8 -1.3 -2.1; 0.8 1.0 -1.5; 4.0
M 0.0 -2.7; 1.2 -2.4 -3.6; -1.0 0.8 -0.4; 1.5
Vancomycin IV 0.9 -5.0; 1.8 -0.4 -4.1; 1.3 1.0 -4.7; 3.7
M -0.8 -4.4; 1.0 1.2 0.1; 3.4 1.8 -0.9; 2.9
Dobutamine IV 2.5 -1.0; 3.7 -0.2 -3.1; 1.8
M -3.5 -4.4; -2.8 -2.1 -3.1; -1.6
Fluconazole IV -1.0 -3.6; 0.9
M 2.2 -1.6; 2.8
Metronidazole IV -0.7 -4.6; 1.7
M 3.2 -0.6; 5.0
Paracetamol IV 0.4 -2.0; 3.3
M 4.1 -1.8; 6.2
IV, I.V.Station®; M, manual.
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FIgURe 1 | Box-plot of accuracy in reconstitution, dilution and final product between I.V. Station® and manual preparations (IVS: I.V. Station®; M: manual). 
(A): Accuracy in reconstitution. (B): Accuracy in dilution. (C): Accuracy of the final drug.
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iatrogenic events. Thus, the incidence of medication errors 
that occur during the care of extremely preterm newborns is 
reported to be quite high near 57%, compared to 3% when 
caring for full-term infants (Kugelman et al., 2008). In this 
patient category, adequate drug dosing requires serial dilutions 
and manipulation of the solutions, thus increasing the odds 
of an incorrect dose, concentration, and contamination 
of the final solution (Kugelman et al., 2008). As previously 
demonstrated in the literature, manually-prepared drugs in 
the ICU setting frequently show significant deviations from 
the target concentration, while automated-prepared drugs 
show less variability (Allen et al., 1995; Parshuram et al., 2003; 
Wheeler et al., 2008; Dehmel et al., 2011; Seger et al., 2012). 
This wide variability can lead to harmful consequences, such 
as adverse reactions due to overdosing or loss of efficacy due 
to underdosing (Kugelman et al., 2008). In a recent study, 
Iwamoto et al. demonstrated that the robotic preparation 
of antineoplastic drugs using APOTECA-chemo had 
higher accuracy and a lower absolute dose error compared 
to manual preparation. The risk of overdose significantly 
reduced, resulting in safer cancer treatment (Iwamoto et al., 
2017). Geersing et al. also demonstrated that APOTECA-
chemo preparations were microbiologically safe (Geersing 
et al., 2019).
Our data confirm that the I.V. Station® can reduce 
variability and thus improve accuracy at any step of the 
medication process (Table 2, Figure 1). Although manual 
method results in a tolerable median error, it shows wider 
variability among different preparations, with some dropping 
outside of the ±5% admitted interval. As recently reported 
in the literature, ward-based manually prepared solutions 
can deviate in concentration conformity more often than 
machine-made solutions (Kugelman et al., 2008). As can be 
expected in any operator-dependent process, the accuracy 
of the final therapy could not be guaranteed, without the 
possibility to identify and discard those preparations which 
do not respect the desired concentration. A centralized, 
automated preparation of standardized solutions has already 
been proposed as an effective means to reduce preparation 
error in everyday practice (Kugelman et al., 2008).
Unlike manual preparations, the I.V. Station® is set to 
automatically discard preparations that do not respect 
the predetermined range of accuracy. Hence, our data are 
consistent with this hypothesis. For this reason, the margin 
of error observed with the I.V. Station® never dropped 
outside the ±5% accuracy interval in any of the steps analyzed 
(reconstitution, dilution, final product). Therefore, the 
I.V. Station® may guarantee a high level of concentration 
conformity, and thus increased drug safety. Moreover, when 
combined with other strategies (i.e., electronic medical record, 
computerized order entry, and bar-code system) robotic 
technology is expected to reduce the risk of prescription 
and administration errors, improving safety and workflow 
efficiency (Dehmel et al., 2011).
Robotic preparation appears to be safer not only for the 
patient but also for the staff. Seger et al. observed a significant 
reduction in potentially harmful staff events after the TA
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introduction of robotic preparation of an antineoplastic drug 
(Seger et al., 2012). Although we did not evaluate staff events 
in relation to the therapeutic process, we could speculate that 
advantages similar to those reported by Seger et al. would 
occur in our NICU, where work-related risk is high. Robotic 
technology offers the opportunity not only for safer but also 
for a more cost-effective medication process. Moreover, 
Seger et al. found out that by introducing robotic preparation 
of an antineoplastic drug and adjuvant medications, they 
considerably reduced ancillary costs associated with several 
components. The savings accounted for 60% of the overall 
cost, and when annualized for the number of antineoplastics 
prepared in a year, they would have saved $115,500 in material 
costs (Seger et al., 2012).
Our data confirm that robotic technology reduces the cost 
administering most drugs, especially when multiple preparations 
are needed. Benefits are expected to be even more remarkable 
when considering the huge number of medications prescribed in 
FIgURe 2 | Estimated cost savings. The robotic preparations result more expensive than the manual one in the red boxes. As the amount of preparations 
increases, I.V. Station® leads to an optimization of materials consumption and costs, becoming equal to manual preparation (white boxes) or even less expensive 
(green boxes).
FIgURe 3 | Times for preparations. Time needed for the preparation of each drug separately (IVS: I.V. Station®).
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the NICU, since the more preparations of the same drug that are 
required within short period, the greater are the advantage, as the 
robot may use the same vial.
As shown in Figure 2, if the number of doses prepared 
through the I.V. Station® is low, the material consumption is high 
in a first step but could be subsequently amortized by an increase 
in the number of preparations. The greater is the number of 
patients requiring the same therapy in a given period, the more 
remarkable the advantage. Therefore, the I.V. Station® leads to 
greater savings in the long run, provided that the final product 
is consumed within the time frame in which the diluted solution 
remains stable.
Hence, the robotic process could be further optimized by 
consistently using the I.V. Station®, to expand production to 
other departments of the same hospital or other NICUs in 
the territory, building a distribution network with centralized 
production. Furthermore, automated-preparation of medications 
allow nurses to save time during the therapeutic process. 
Although manual preparation is rapid for some drugs (i.e., 
paracetamol, which is ready for use), some drugs require multiple 
dilutions and a significant amount of time to be prepared (i.e., 
teicoplanin) (Figure 3).
The I.V. Station® prepares multiple drugs in a sequence that 
can be withdrawn at once (Figure 4), thus inducing relevant 
time savings compared to manual preparation. For liquid 
drugs that are ready to be used (as paracetamol), the advantage 
commences when the number of doses to be prepared is 
more than nine. In analyzing the other compounds, savings 
begin with a lower number of preparations and is highest 
with teicoplanin, as robotic process saves a great deal of time 
from the first administration. With costs savings, the more 
intravenous therapy required, the greater the advantage in 
terms of procedural efficiency. The saved “drug preparation 
time” can, therefore, be used for the direct care of the neonate. 
While the robot is working, the nurse could remain at the 
patient’s bedside to better assist the baby wherever necessary, 
engage and educate the family, in an effort to provide the best 
care possible. As a result, the bond between the newborn and 
parents can be strongly enhanced. All these positive effects are 
not currently quantifiable but could represent a strong point 
in favor of smart robotics in the NICU setting.
Our study has some limitations. We analyzed a small number 
of injectable drugs, which only represents a small proportion of 
the intravenous therapy administered in the NICU. However, 
we have included the compounds that are the most commonly 
prescribed by neonatologists. Our analysis did not include 
costs concerning electricity, machine maintenance, or days 
of detention due to possible damage or failure of the robot. 
However, in 2018, the inactivity rate of the I.V. Station® was 
almost negligible (2.5% = 9.2/365 days), with a minimum time 
lag of 4.8 min up to 2.5 days of the stop. Seger et al. found some 
mechanical or software failure events associated with robotic 
preparations, which did not have harmful consequences on 
the patients but affected workflow efficiency and wasting of 
some medication (Seger et  al., 2012). These are important 
limitations of robotic technology. The impact of ancillary 
costs, robot, or software failure, must be further characterized, 
and strategies for avoiding waste need to be implemented. 
Another limitation is that analysis of the microbiological 
safety of robotic compounds was not analyzed in this study. 
However, a preliminary microbiological analysis confirming 
the bacteriological safety was performed in 2013 before the 
implementation of the robot in our Unit. Based on the standard 
operating procedures of the I.V. Station®, the sterility of drug 
preparations is guaranteed for 24 h.
Based on our on-site microbiological surveillance, we have 
extended the sterility for liquid preparations for up to 72 h. 
Over 1 year, we analyzed microbiological cultures taken both 
from pharmaceutical preparations and the surface of the robot 
(daily during the first month, then weekly for three months and 
FIgURe 4 | Estimated time savings. I.V. Station® expected time-saving compared to manual preparation. With a low number of doses, I.V. Station® could result in 
more time-consuming than the manual method (red boxes). With the increase of preparations, I.V. Station® leads to a progressive optimization of the preparation 
process (green boxes).
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monthly for the rest of the year), which turned out to be negative 
(unpublished data). Lastly, the observation period was limited 
to 2 months after the introduction of the robot. To better define 
the advantages of the I.V. Station® in clinical practice, further 
analysis must be conducted on a greater number of compounds, 
and during a more extended period.
CONClUsIONs
Our data demonstrate that the I.V. Station® may support the 
therapeutic process in the NICU. Benefits are related to accuracy 
in drug preparation, cost, and time-saving. These advantages 
are particularly important in the NICU, where the I.V. Station® 
could facilitate the high complexity of care, nursing workload, 
and the significant amount of intravenous therapy typically 
administered. Robotics may positively impact the patients 
and their families, by allocating the human resources (i.e., 
nurses’ time and effort) to neonatal care. A possible reduction 
in medication errors due to the introduction of automated 
procedures is also possible: however, additional studies are 
required to confirm this hypothesis. Efforts should be directed at 
drugs that are not currently available in vials, in order to extend 
the number of pharmaceutical drugs that can be prepared by 
the robot.
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